glp-1 and anastrozole A trio of large observational studies reported at the San Antonio Breast Cancer Symposium (SABCS) 2025 suggest that receptor agonists may improve outcomes in some women with breast cancer. Two studies Evolution of GLP‐1 Receptor Agonists

there were no adverse events [50]

Individuals on chemotherapy, those with glutathione synthase deficiency, and patients on certain medications (including some antiretrovirals) should obtain provider clearance

The clinical proof that supplying them by injection moves the scale is not there

Rather than defaulting everyone to dual compounds, genetic insights can prioritize single-agent optimization or justify dual therapy based on individual biology rather than trial-and-error

(4) In another study, (5) six growth hormone-deficient test subjects facing growth failure were presented with growth hormone-stimulating peptides

The compound reliably raised GH and IGF-1, but the two largest or longest trials the Alzheimers study and the two-year healthy-elderly study failed to show benefit on the outcomes that actually matter (cognition/function and strength/function, respectively)